Abstract:Background Systemic sclerosis (SSc) is an autoimmune disease characterized with multiple organ fibrosis. Previous studies showed transcription factor early growth response 1 (Egr1) overexpressed in the lesional skin of SSc patients, as well as Egr1 inducible genes1. Egr1 forms a positive feedback loop with master pro-fibrotic cytokine TGF and thus promotes fibrosis. Objectives To investigate the anti-fibrotic effect of a novel DMARD iguratimod in scleroderma models and patient skin grafts. Methods We used iguratimod to treat TGF-stimulated human skin fibroblast, bleomycin induced mice, tight skin 1 (TSK-1) mice and SSc skin grafts. The bleomycin model contained pre-establish fibrosis and late onset treatment. The skin grafts came from three SSc patients and was planted into irradiated nude mice. Results Iguratimod down-regulated egr1 expression in human skin fibroblast, with decreased collagen production and a-SMA expression. Knocking down Egr1 in fibroblast could mimic these effects. Both oral and topical iguratimod could reduce dermal thickening and collagen deposition in bleomycin induced skin fibrosis. a-SMA (+) myofibroblast counts, as well as Egr1 (+) and/or TGF (+) fibroblast counts in iguratimod treated groups were significantly less than the controls. Similarly, topical iguratimod ameliorated fibrosis with deduced dermal thickening in TSK-1 mice. Of note, 5-week iguratimod local injection remarkably reduced collagen content in skin grafts from three SSc patients. Staining of Egr1 and TGF in skin tissue were inhibited after iguratimod treatment simultaneously. Conclusion We found the potential of iguratimod to treat SSc, which was characterized as an Egr1 inhibitor. Further clinical investigation is needed to establish its safety and efficacy. References [1] Bhattacharyya S, Sargent JL, Du P, et al. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PloS one 2011;6(9):e23082 doi: 10.1371/journal.pone.0023082 [2] Chen SJ, Ning H, Ishida W, et al. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. The Journal of biological chemistry 2006;281(30):21183-97 doi: 10.1074/jbc.M603270200 [2] Wu M, Melichian DS, de la Garza M, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. The American journal of pathology 2009;175(3):1041-55 doi: 10.2353/ajpath.2009. Acknowledgement This work is supported by National Natural Science Foundation of China (81601401). Disclosure of Interests None declared

THU0355 IGURATIMOD MIGHT TREAT SCLERODERMA WITH INTERRUPTED EGR1/TGF-? LOOP

Iguratimod Attenuated Fibrosis in Systemic Sclerosis Via Targeting Early Growth Response 1 Expression.

Iguratimod inhibits skin fibrosis by regulating TGF-β1/Smad signalling pathway in systemic sclerosis

Smad-Independent Transforming Growth Factor-β Regulation of Early Growth Response-1 and Sustained Expression in Fibrosis

Paclitaxel Modulates Tgf Beta Signaling in Scleroderma Skin Grafts in Immunodeficient Mice

Isoform-selective TGF-β3 inhibition for systemic sclerosis

Tanshinone IIA ameliorates the development of dermal fibrosis in systemic sclerosis

Inhibition of the Hedgehog Pathway Leads to Antifibrotic Effects in Dermal Fibrosis

Role of endothelin-1 in the skin fibrosis of systemic sclerosis

Collagen triple helix repeat containing-1 exerts antifibrotic effects on human skin fibroblast and bleomycin-induced dermal fibrosis models

Targeting CD13/aminopeptidase N as a novel therapeutic approach for scleroderma fibrosis

Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma

Mir-3606-3p Alleviates Skin Fibrosis by Suppressing Fibroblast Inflammation and Migration Via Inhibiting GAB1 and ITGAV

Bone Morphogenetic Protein Antagonist Gremlin-1 Increases Myofibroblast Transition in Dermal Fibroblasts: Implications for Systemic Sclerosis

Modulation by 17,20S(OH)2pD of Fibrosis-Related Mediators in Dermal Fibroblast Lines from Healthy Donors and from Patients with Systemic Sclerosis

Iguratimod Suppresses Plasma Cell Differentiation and Ameliorates Experimental Sjögren’s Syndrome in Mice by Promoting TEC Kinase Degradation

PDGF Promotes Dermal Fibroblast Activation via a Novel Mechanism Mediated by Signaling Through MCHR1

Iguratimod suppresses plasma cell differentiation and ameliorates experimental Sjögren's syndrome in mice by promoting TEC kinase degradation

Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis

Tanshinone IIA ameliorates the bleomycin-induced endothelial-to-mesenchymal transition via the Akt/mTOR/p70S6K pathway in a murine model of systemic sclerosis

Dissection of the mechanism of traditional Chinese medical prescription-Yiqihuoxue formula as an effective anti-fibrotic treatment for systemic sclerosis